THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
发明人:
WEISSMAN, IRVING L.,MAJETI, RAVINDRA,ALIZADEH, ARASH ASH,CHAO, MARK P.
申请号：
CA2771336
公开号：
CA2771336C
申请日:
2010.09.15
申请国别(地区):
CA
年份:
2019
代理人:
摘要：
Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47； and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33； CD96； CD44； CD123； CD97； CD99； PTHR2； and HAVCR2.
